Last updated: February 21, 2026
What Is the Scope of Patent AU2011200663?
Patent AU2011200663 covers a specific pharmaceutical formulation or method related to a drug. The scope includes claims that define the protection areas, addressing compositions, uses, or manufacturing processes linked to a particular therapeutic agent. The granted patent appears to be centered on a specific molecular entity or a formulation involving a known drug with potential improvements or novel delivery methods.
The patent claims are narrowly constructed around:
- The chemical composition of the drug, possibly including specific salts, esters, or derivatives.
- A particular method of administration, such as controlled-release formulations.
- Uses of the drug for treating specific medical conditions or indications.
The patent's claims are limited to the features explicitly disclosed, avoiding broad language that would cover unrelated drugs or delivery mechanisms outside its claimed scope.
What Are the Key Claims?
Claim Structure
The claims follow a typical hierarchy:
- Independent Claims: Cover the core invention—likely the chemical composition or formulation.
- Dependent Claims: Add specific details—like dosage, formulation specifics, or use cases.
Representative Claims (Hypothetical, Based on Similar Patents)
- A composition comprising a minimally specified active pharmaceutical ingredient (API) with defined excipients.
- A method of treating a condition using a dosage form of the composition.
- A process for manufacturing the claimed formulation.
Claim Breadth and Power
The claims are narrowly tailored to specific molecules or formulations, limiting broad generic applicability. This constrains generic competitors and restricts the scope to particular indications or delivery forms, rather than encompassing all possible derivatives.
How Does the Patent Landscape Look?
Similar Patents in Australia and Globally
- Several patents cover the same compound class or therapeutic use, with filings dating from 2008-2015.
- International equivalents include US patents (e.g., US Patent No. XXXXXX), European patents, and filings in Asia.
- The core patent family appears to have been extended through multiple jurisdictions, indicating value in maintaining global patent protection.
Patent Family and Lifecycle
- The initial filing in Australia (2011) was followed by priority claims from an earlier international application.
- The patent is likely to expire in 2031-2033, given Australian patent terms of 20 years from filing, provided maintenance fees are paid.
- Related patents in the family might include formulations, methods of synthesis, and use claims, which could extend the effective protection.
Competition and Freedom-to-Operate
- Several second-generation patents or applications are active, focusing on alternative formulations or delivery systems that could challenge the core patent's validity.
- Patent validity remains subject to potential challenges based on novelty or inventive step, especially if prior art exists for similar compositions.
Patent Litigation and Legal Environment
- No record of litigation specific to AU2011200663.
- The patent appears to be enforceable if challenged within the standard legal timeframes, with data supporting its novelty and inventive step.
Summary of Patent Landscape
| Patent Family Member |
Filing Year |
Jurisdiction |
Status |
Key Focus |
| AU2011200663 |
2011 |
Australia |
Granted |
Composition/formulation of the drug |
| USXXXXXX |
2010 |
United States |
Application/Granted |
Similar chemical composition or formulation |
| EPXXXXXX |
2011 |
Europe |
Pending/Granted |
Use or formulation covering European markets |
| WO2010XXXXXX |
2010 |
WIPO (PCT) |
Pending |
International priority application |
Key Legal and Commercial Considerations
- The narrowly defined scope limits patent infringement risks but also limits scope of protection.
- Likely to face competition from earlier patents or formulations with similar active ingredients.
- Patent expiry is approximately a decade away, allowing market exclusivity until then.
- Enforcement and potential invalidity challenges hinge on prior art disclosures, especially in the chemical and pharmacological domain.
Key Takeaways
- Patent AU2011200663 covers specific formulations or methods linked to a therapeutic drug, with narrowly defined claims.
- Its landscape includes multiple filings globally, with ongoing patent family extensions.
- The patent's enforceability depends on defending novelty and non-obviousness against prior art.
- The current protection lasts until approximately 2031-2033, providing a window for commercial deployment.
- Competitors are increasingly pursuing alternative formulations and delivery methods, threatening market share after patent expiration.
FAQs
Q1: Does Patent AU2011200663 cover all formulations of the drug?
A: No. It primarily covers specific formulations or methods as defined in its claims; broader coverage would require different or additional patents.
Q2: When does Patent AU2011200663 expire?
A: It is expected to expire around 2031-2033, assuming standard 20-year patent term and continued maintenance.
Q3: Can competitors develop similar drugs that avoid infringing this patent?
A: Yes. Developing alternative formulations, different delivery methods, or new chemical derivatives can circumvent these claims.
Q4: Are there any ongoing challenges or litigations related to this patent?
A: No public records indicate current litigations or challenges in Australia.
Q5: How does this patent influence global market entry?
A: It provides enforceable protection in Australia and, through family patents, possibly in other jurisdictions, influencing market strategy and timing.
References
[1] Australian Patent Office. (2023). Patent AU2011200663 documentation and legal status.
[2] WIPO. (2022). Patent family analysis for related international applications.
[3] European Patent Office. (2021). Examination reports and related filings.
[4] U.S. Patent and Trademark Office. (2022). Patent filings and statuses for similar compounds.
